Please login to the form below

Not currently logged in
Email:
Password:

Crescendo Biologics appoints CFO

Theodora Harold joins the drug discovery firm

Crescendo Biologics Theodora HaroldCambridge, UK-based Crescendo Biologics has appointed Theodora Harold as its new chief financial officer.

Harold brings 20 years of pharmaceutical and corporate finance industry experience to the role, with particular expertise in growing and early stage biotech companies.

She joins from PsiOxus Therapeutics where she served as chief financial officer, and has also held a number of positions at Cytomyx Holdings, OrthoMimetics, and Mission Therapeutics.

Dr Peter Pack, chief executive officer of Crescendo Biologics, said: “Theo's appointment as Crescendo's new chief financial officer places us in an excellent position to drive ahead with our ambitious plans to create a high value pipeline of differentiated Humabody therapeutics for treating cancer indications with substantial unmet need.

“The experience that she brings to Crescendo strengthens the existing management team and is crucial in allowing us to continue building both strategic and financial value in the company.”

1st November 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics